Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients

Giulia Morsica, Giampaolo Bianchi, Sabrina Bagaglio, Camilla Conte, Stefania Salpietro, Lucy Porrino, Caterina Uberti-Foppa

Research output: Contribution to journalArticle

Abstract

The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.

Original languageEnglish
Pages (from-to)317-321
Number of pages5
JournalNew Microbiologica
Volume34
Issue number3
Publication statusPublished - Jul 2011

Keywords

  • Darunavir
  • HCV
  • HIV
  • Liver toxicity
  • Ritonavir

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients'. Together they form a unique fingerprint.

  • Cite this